Abstract
Aim:
The aim of this study was to investigate the antitumoral activity of human urine extract against myelodysplastic syndrome (MDS)-derived MUTZ-1 cells in vitro and in vivo.
Methods:
The MDS–refractory anemia with excess of blasts (RAEB)-derived MUTZ-1 cell line was used to examine the effects of a human urine preparation, CDA-2, on the induction of growth arrest and apoptosis. Apoptotic proteins, including caspase family, Bcl-2 family, the inhibitor of apoptosis protein (IAP) family, and the FLICE-like inhibitory protein (FLIP), as well as cell cycle-associated proteins were studied. The phosphoinositide 3 kinase (PI3K)/Akt survival signaling pathway and the NF-κB pathway were also examined. The caspase-3 inhibitor Z-DEVD-fmk was used to examine the involvement of caspase-3 and poly (ADP-ribose) polymerase (PARP). PI3K inhibitor LY294002 was used to examine the involvement of the PI3K/Akt signaling pathway in this apoptosis-inducing effect. MUTZ-1 cell xenografted serious combined immunodeficiency disease mice were used for the in vivo study.
Results:
We found that CDA-2 could induce growth arrest and apoptosis of MUTZ-1 cells in vitro and in vivo. The main mechanisms were related to the inhibition of PI3Kp110α expression at the transcriptional level, which inactivated the phosphorylation of Akt involving the prevention NF-κB phosphorylation and nuclear translocation, the downregulation of the IAP family and FLIPL protein, and the dephosphorylation of the Bad protein, which then triggered the activation of the caspase cascades. This phenomenon could be inhibited by the PI3K inhibitor LY294002 and caspase-3 inhibitor Z-DEVD-fmk.
Conclusion:
Our results demonstrate the presence of active components in the human urine extract that can induce the growth arrest and apoptosis of MDS–RAEB-derived MUTZ-1 cells and may involve the PI3K/Akt signaling pathway in a caspase-3-dependent manner. This may provide new insights for the treatment of high-risk MDS.
Similar content being viewed by others
Article PDF
References
Mufti G, List AF, Gore SD, Ho AY . Myelodysplastic syndrome. Hematology Am Soc Hematol Educ Program 2003; 176–99.
Look AT . Molecular pathogenesis of MDS. Hematology Am Soc Hematol Educ Program 2005; 156–60.
Jaffe ES, Harris NL, Stein H, Vardiman JW, editors. World Health Organization classification of tumors. Pathology and genetics of tumours of haematopoietic and lymphoid tissues. Lyon (France): IARC Press; 2001.
Parker JE, Mufti GJ . The myelodysplastic syndromes: a matter of life or death. Acta Haematol 2004; 111: 78–99.
Burzynski SR . Antineoplastons: history of the research (I). Drugs Exp Clin Res 1986; 12 (suppl1): 1–9.
Badria F, Mabed M, Khafagy W, Abou-Zeid L . Potential utility of antineoplaston A-10 levels in breast cancer. Cancer Lett 2000; 155: 67–70.
Lin WC, Wu YW, Lai TY, Liau MC . Effect of CDA-II, urinary preparation, on lipofuscin, lipid peroxidation and antioxidant systems in young and middle-aged rat brain. Am J Chin Med 2001; 29: 91–9.
Lin WC, Liao YC, Liau MC, Lii CK, Sheen LY . Inhibitory effect of CDA-II, a urinary preparation, on aflatoxin B(1)-induced oxidative stress and DNA damage in primary cultured rat hepatocytes. Food Chem Toxicol 2006; 44: 546–51.
Yao CJ, Lai GM, Chan CF, Yang YY, Liu FC, Chuang SE . Differentiation of pheochromocytoma PC12 cells induced by human urine extract and the involvement of the extracellular signal-regulated kinase signaling pathway. J Altern Complement Med 2005; 11: 903–8.
Steube KG, Gignac SM, Hu ZB, Teepe D, Harms D, Kabisch H, et al. In vitro culture studies of childhood myelodysplastic syndrome: establishment of the cell line MUTZ-1. Leuk Lymphoma 1997; 25: 345–63.
Drexler HG . Malignant hematopoietic cell lines: in vitro models for the study of myelodysplastic syndromes. Leuk Res 2000; 24: 109–15.
Fischer U, Schulze-Osthoff K . Apoptosis-based therapies and drug targets. Cell Death Differ 2005; 12 (Suppl 1): 942–61.
Urbano A, Gorgun G, Foss F . Mechanisms of apoptosis by the tyrphostin AG957 in hematopoietic cells. Biochem Pharmacol 2002; 63: 689–92.
Chandrasekar B, Vemula K, Surabhi RM, Li-Weber M, Owen-Schaub LB, Jensen LE, et al. Activation of intrinsic and extrinsic proapoptotic signaling pathways in interleukin-18-mediated human cardiac endothelial cell death. J Biol Chem 2004; 279: 20 221–33.
Verhagen AM, Ekert PG, Pakusch M, Silke J, Connolly LM, Reid GE, et al. Identification of DIABLO, a mammalian protein that promotes apoptosis by binding to and antagonizing IAP proteins. Cell 2000; 102: 43–53.
Kerbauy DB, Deeg HJ . Apoptosis and antiapoptotic mechanisms in the progression of myelodysplastic syndrome. Exp Hematol 2007; 35: 1739–46.
Kerbauy DM, Lesnikov V, Abbasi N, Seal S, Scott B, Deeg HJ . NF-kappaB and FLIP in arsenic trioxide (ATO)-induced apoptosis in myelodysplastic syndromes (MDSs). Blood 2005; 106: 3917–25.
Sun Y . E3 ubiquitin ligases as cancer targets and biomarkers. Neoplasia 2006; 8: 645–54.
Lee R, Collins T . Nuclear factor-kappaB and cell survival: IAPs call for support. Circ Res 2001; 88: 262–4.
Stehlik C, de Martin R, Kumabashiri I, Schmid JA, Binder BR, Lipp J . Nuclear factor (NF)-kappaB-regulated X-chromosome-linked iap gene expression protects endothelial cells from tumor necrosis factor alpha-induced apoptosis. J Exp Med 1998; 188: 211–6.
Catz SD, Johnson JL . Transcriptional regulation of bcl-2 by nuclear factor kappa B and its significance in prostate cancer. Oncogene 2001; 20: 7342–51.
Micheau O, Lens S, Gaide O, Alevizopoulos K, Tschopp J . NF-kappaB signals induce the expression of c-FLIP. Mol Cell Biol 2001; 21: 5299–305.
Dolcet X, Llobet D, Pallares J, Matias-Guiu X . NF-kappaB in development and progression of human cancer. Virchows Arch 2005; 446: 475–82.
Woo M, Hakem R, Soengas MS, Duncan GS, Shahinian A, Kagi D, et al. Essential contribution of caspase 3/CPP32 to apoptosis and its associated nuclear changes. Genes Dev 1998; 12: 806–19.
Burkle A . Physiology and pathophysiology of poly(ADP-ribosyl) ation. Bioessays 2001; 23: 795–806.
Tong WM, Cortes U, Wang ZQ . Poly (ADP-ribose) polymerase: a guardian angel protecting the genome and suppressing tumorigenesis. Biochim Biophys Acta 2001; 1552: 27–37.
Steelman LS, Pohnert SC, Shelton JG, Franklin RA, Bertrand FE, McCubrey JA . JAK/STAT, Raf/MEK/ERK, PI3K/Akt and BCR-ABL in cell cycle progression and leukemogenesis. Leukemia 2004; 18: 189–218.
Woodgett JR . Recent advances in the protein kinase B signaling pathway. Curr Opin Cell Biol 2005; 17: 150–7.
Nyàkern M, Tazzari PL, Finelli C, Bosi C, Follo MY, Grafone T, et al. Frequent elevation of Akt kinase phosphorylation in blood marrow and peripheral blood mononuclear cells from high-risk myelodysplastic syndrome patients. Leukemia 2006; 20: 230–8.
Lee S, Choi EJ, Jin C, Kim DH . Activation of PI3K/Akt pathway by PTEN reduction and PIK3CA mRNA amplification contributes to cisplatin resistance in an ovarian cancer cell line. Gynecol Oncol 2005; 97: 26–34.
Hayakawa J, Ohmichi M, Kurachi H, Kanda Y, Hisamoto K, Nishio Y, et al. Inhibition of Bad phosphorylation either at serine-112 via extracellular signal-regulated protein kinase cascade or at serine-136 via Akt cascade sensitizes human ovarian cancer cells to cisplatin. Cancer Res 2000; 60: 5988–94.
Datta SR, Brunet A, Greenberg ME . Cellular survival: a play in three Akts. Genes Dev 1999; 13: 2905–27.
Kennedy SG, Wagner AJ, Conzen SD, Jordán J, Bellacosa A, Tsichlis PN, et al. The PI3-kinase/Akt signaling pathway delivers an anti-apoptotic signal. Genes Dev 1997; 11: 701–13.
Shayesteh L, Lu Y, Kuo WL, Baldocchi R, Godfrey T, Collins C, et al. PIK3CA is implicated as an oncogene in ovarian cancer. Nat Genet 1999; 21: 99–102.
Béraud C, Henzel WJ, Baeuerle PA . Involvement of regulatory and catalytic subunits of phosphoinositide 3-kinase in NF-kappaB activation. Proc Natl Acad Sci USA 1999; 96: 429–34.
Braun T, Carvalho G, Coquelle A, Vozenin MC, Lepelley P, Hirsch F, et al. NF-kappaB constitutes a potential therapeutic target in high-risk myelodysplastic syndrome. Blood 2006; 107: 1156–65.
Sanz C, Richard C, Prosper F, Fernandez-Luna JL . Nuclear factor kappa B is activated in myelodysplastic bone marrow cells. Haematologica 2002; 87: 1005–6.
Takada Y, Kobayashi Y, Aggarwal BB . Evodiamine abolishes constitutive and inducible NF-kappaB activation by inhibiting IkappaBalpha kinase activation, thereby suppressing NF-kappaB-regulated antiapoptotic and metastatic gene expression, up-regulating apoptosis, and inhibiting invasion. J Biol Chem 2005; 280: 17 203–12.
Baldwin AS Jr, Azizkhan JC, Jensen DE, Beg AA, Coodly LR . Induction of NF-kappa B DNA-binding activity during the G0-to-G1 transition in mouse fibroblasts. Mol Cell Biol 1991; 11: 4943–51.
Joyce D, Bouzahzah B, Fu M, Albanese C, D'Amico M, Steer J, et al. Integration of Rac-dependent regulation of cyclin D1 transcription through a nuclear factor-kappaB-dependent pathway. J Biol Chem 1999; 274: 25 245–9.
Weinberg RA . The retinoblastoma protein and cell cycle control. Cell 1995; 81: 323–30.
Armstrong JS . Mitochondrial medicine: pharmacological targeting of mitochondria in disease. Br J Pharmacol 2007; 151: 1154–65.
Oltvai ZN, Milliman CL, Korsmeyer SJ . Bcl-2 heterodimerizes in vivo with a conserved homolog, Bax, that accelerates programmed cell death. Cell 1993; 74: 609–19.
Del Poeta G, Venditti A, Del Principe MI, Maurillo L, Buccisano F, Tamburini A, et al. Amount of spontaneous apoptosis detected by Bax/Bcl-2 ratio predicts outcome in acute myeloid leukemia (AML). Blood 2003; 101: 2125–31.
Dlugosz PJ, Billen LP, Annis MG, Zhu W, Zhang Z, Lin J, et al. Bcl-2 changes conformation to inhibit Bax oligomerization. EMBO J 2006; 25: 2287–96.
Sedletska Y, Giraud-Panis MJ, Malinge JM . Cisplatin is a DNA-damaging antitumour compound triggering multifactorial biochemical responses in cancer cells: importance of apoptotic pathways. Curr Med Chem Anticancer Agents 2005; 5: 251–65.
Ryningen A, Ersvaer E, Oyan AM, Kalland KH, Vintermyr OK, Gjertsen BT, et al. Stress-induced in vitro apoptosis of native human acute myelogenous leukemia (AML)cells shows a wide variation between patients and is associated with low BCL-2:Bax ratio and low levels of heat shock protein 70 and 90. Leuk Res 2006; 30: 1531–40.
Carter BZ, Mak DH, Schober WD, McQueen T, Harris D, Estrov Z, et al. Triptolide induces caspase-dependent cell death mediated via the mitochondrial pathway in leukemic cells. Blood 2006; 108: 630–7.
Dan HC, Sun M, Kaneko S, Feldman RI, Nicosia SV, Wang HG, et al. Akt phosphorylation and stabilization of X-linked inhibitor of apoptosis protein (XIAP). J Biol Chem 2004; 279: 5405–12.
Yamamoto K, Abe S, Nakagawa Y, Suzuki K, Hasegawa M, Inoue M, et al. Expression of IAP family proteins in myelodysplastic syndromes transforming to overt leukemia. Leuk Res 2004; 28: 1203–11.
Benesch M, Platzbecker U, Ward J, Deeg HJ, Leisenring W . Expression of FLIP(Long) and FLIP(Short) in bone marrow mono–nuclear and CD34+ cells in patients with myelodysplastic syndrome: correlation with apoptosis. Leukemia 2003; 17: 2460–6.
Author information
Authors and Affiliations
Corresponding author
Additional information
This work was partly supported by the Chinese National Foundation for the Development of High Technology (863 program; No 2006AA02A405).
Rights and permissions
About this article
Cite this article
Huang, J., Yang, M., Liu, H. et al. Human urine extract CDA-2 induces apoptosis of myelodysplastic syndrome-derived MUTZ-1 cells through the PI3K/Akt signaling pathway in a caspase-3-dependent manner. Acta Pharmacol Sin 29, 951–964 (2008). https://doi.org/10.1111/j.1745-7254.2008.00826.x
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1111/j.1745-7254.2008.00826.x
Keywords
This article is cited by
-
miR-124 radiosensitizes human glioma cells by targeting CDK4
Journal of Neuro-Oncology (2013)
-
CDA-2 induces cell differentiation through suppressing Twist/SLUG signaling via miR-124 in glioma
Journal of Neuro-Oncology (2012)